Download Kineta`s Novel Antiviral Drugs Show Encouraging

PRESS RELEASE
Kineta’s Novel Antiviral Drugs Show Encouraging
Efficacy Against Dengue And SARS Viruses
New data presented at International Conference on Antiviral Research
SEATTLE, WA, May 19, 2014--Kineta, Inc. a biotechnology company focused on the development of
immune modulating drugs for critical disease areas, announced today that its scientists reported
encouraging new data from its innate- immune agonist program showing drug activity in vivo against
Dengue virus type 2. The molecules induce an innate immune response and generate a broad antiviral
cellular defense. That response inhibits diverse viruses including the Flu, SARS, RSV as well as Dengue.
These diseases affect millions of people globally and represent a significant unmet need. Traditional antiviral drug design has failed to identify effective broad spectrum drugs. Antivirals that target virus directly
often become ineffective over time owing to the rapid emergence of resistant virus strains.
“We have identified a novel class of small molecule antiviral drugs that trigger a natural immune
response by targeting the innate immune transcription factor, IRF-3, a critical first responder that is
essential for suppressing viral replication and clearing infection, “ said Kineta’s Dr. Ikenna Madu, Ph.D.
“This potent inhibition of viral pathogens represents a favorable new target for broad spectrum antiviral
drug development in a space that desperately needs innovative solutions,” Dr. Madu added.
The findings were presented at the recent 27th International Conference on Antiviral Research held in
North Carolina.
Jennifer Dent, President of BIO Ventures for Global Health, which engages private industry in global
health initiatives praised Kineta for, “advancing innovative new research solutions for diseases which in
today’s world are affecting both developing and developed nations. The recent MERS outbreaks and
growing incidence of Dengue fever show how these diseases can affect everyone.”
About Kineta
Kineta, Inc. is a Seattle-based privately held biotechnology company specializing in clinical advancement
of novel drug candidates derived from leading edge scientific research. Our world class scientists are
pioneers in developing life-changing classes of new drugs designed to be more effective and safer than
current medicines. Kineta seeks to improve the lives of millions of people suffering from autoimmune
and viral diseases and from severe pain. Our progressive business model focuses on targeting unmet
medical needs and rapid achievement of important clinical milestones. For more information on Kineta,
Inc. visit our website, www.Kinetabio.com
Kineta, Inc. visit our website, www.Kinetabio.com
Contact Dan Eramian 206-378-0400 [email protected]
NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical
and clinical studies anticipated drug effects in human subject, regulatory submissions and financial performance. You are cautioned that such forward-looking
statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected
results, including without limitation: progress of drug development; intellectual property protection and enforcement; efficacy, and demand for our products;
clinical testing and regulatory approval; changes in legislative, fiscal, and other regulatory measures; and our ability to recruit and train scientists and other key
personnel. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update
any forward-looking statement to reflect events or circumstances after the issuance of this press release.